NCT00955682View on ClinicalTrials.gov

Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612

PHASE3CompletedINTERVENTIONAL
Enrollment

342

Participants

Timeline

Start Date

August 25, 2009

Primary Completion Date

December 16, 2009

Study Completion Date

September 10, 2012

Conditions
Infections, Meningococcal
Interventions
BIOLOGICAL

Meningococcal vaccine GSK134612

One intramuscular dose (Booster)

BIOLOGICAL

Meningitec™

One intramuscular dose (Booster)

Trial Locations (14)

15140

GSK Investigational Site, Lahti

20520

GSK Investigational Site, Turku

28100

GSK Investigational Site, Pori

33100

GSK Investigational Site, Tampere

48600

GSK Investigational Site, Kotka

60100

GSK Investigational Site, Seinäjoki

70210

GSK Investigational Site, Kuopio

90220

GSK Investigational Site, Oulu

02100

GSK Investigational Site, Espoo

00100

GSK Investigational Site, Helsinki

00930

GSK Investigational Site, Helsinki

04400

GSK Investigational Site, Järvenpää

01300

GSK Investigational Site, Vantaa

01600

GSK Investigational Site, Vantaa

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY